 |
27 Diseases |  |
0 Trials |
|
0 Trials |  |
15 News |  |
- | AZD-5213 / AstraZeneca
Journal: Discovery of 18F Labeled AZD5213 Derivatives as Novel Positron Emission Tomography (PET) Radioligands Targeting Histamine Subtype-3 Receptor. (Pubmed Central) - Sep 21, 2024
The in vitro autoradiographic study in rat brain tissue and the following in vivo PET studies in mice demonstrated sufficient brain uptake but predominantly non-specific distribution in rodent brain. Although these data suggest that [18F]H3-2404 and [18F]H3-2405 are unsuitable as PET tracers for brain imaging of the H3 receptor, this study provides a valuable attempt for optimizing 18F labeled radiotracers based on AZD5213.
- || AZD-5213 / AstraZeneca
Clinical, Journal, Combination therapy: A Three-Way Crossover Study of Pregabalin, Placebo and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination with Pregabalin in Subjects with Painful Diabetic Neuropathy and Good Pain-Reporting Ability. (Pubmed Central) - Aug 20, 2021
The training of study subjects in pain reporting and subsequent enrichment with good pain reporters also did not enable the robust detection of efficacy of pregabalin relative to placebo in a small sample size. Further work is required before recommending the use of "connoisseur" subjects in future neuropathic pain studies.
- | AZD-5213 / AstraZeneca
Journal: Development of [carbonyl-11C]AZ13198083, a novel histamine type-3 receptor radioligand with favorable kinetics. (Pubmed Central) - May 24, 2019
...To address this, we herein report the development of three novel candidate HR radioligands, namely, [ carbonyl-C]AZ13153556 ([ carbonyl-C]4), [ carbonyl-C]AZD5213([ carbonyl-C]5), and [ carbonyl-C]AZ13198083 ([ carbonyl-C]6), and their subsequent preclinical evaluation in nonhuman primates (NHP)...After pre-treatment or displacement with 5 (0.1 mg/mg), a uni-form low distribution of radioactivity across the NHP brain was observed. Collectively, this work demonstrates that [carbonyl-11C]6 is a promising candidate for H3R imaging in human subjects.
- | AZD-5213 / AstraZeneca
Trial completion, Combination therapy: Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability (clinicaltrials.gov) - Jun 23, 2015
P2, N=46, Completed, Sponsor: AstraZeneca
Collectively, this work demonstrates that [carbonyl-11C]6 is a promising candidate for H3R imaging in human subjects. Active, not recruiting --> Completed
- | AZD-5213 / AstraZeneca
Trial completion: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Mar 12, 2015
P2, N=29, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | AZD-5213 / AstraZeneca
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability (clinicaltrials.gov) - Jan 13, 2015
P2, N=46, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=60 --> 46 | Trial primary completion date: Jun 2014 --> May 2015
- | AZD-5213 / AstraZeneca
Enrollment closed, Trial primary completion date: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Dec 7, 2014
P2, N=29, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | N=60 --> 46 | Trial primary completion date: Jun 2014 --> May 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Mar 2015
- | AZD-5213 / AstraZeneca
Enrollment change: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Dec 19, 2013
P2, N=29, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Mar 2015 N=24 --> 29
- |||| AZD-5213 / AstraZeneca
Enrollment open, Combination therapy: Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability (clinicaltrials.gov) - Nov 21, 2013
P2, N=60, Recruiting, Sponsor: AstraZeneca
N=24 --> 29 Not yet recruiting --> Recruiting
- | AZD-5213 / AstraZeneca
Enrollment open: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Sep 12, 2013
P2, N=29, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| AZD-5213 / AstraZeneca
New P2 trial, Combination therapy: Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability (clinicaltrials.gov) - Aug 21, 2013
P2, N=60, Recruiting, Sponsor: AstraZeneca
- | AZD-5213 / AstraZeneca
New P2 trial: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Jul 18, 2013
P2, N=29, Recruiting, Sponsor: AstraZeneca
- |||| AZD-5213 / AstraZeneca
Trial completion: A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment (clinicaltrials.gov) - Feb 20, 2013
P2a, N=81, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| AZD-5213 / AstraZeneca
New P2a trial: A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment (clinicaltrials.gov) - Mar 6, 2012
P2a, N=81, Completed, Sponsor: AstraZeneca
- | AZD-5213 / AstraZeneca
Trial completion: Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects (clinicaltrials.gov) - Oct 23, 2011
P1, N=48, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Completed